This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Johannsson, G. Articles by Albertsson-Wikland, K. Search for Related Content PubMed PubMed Citation Articles by Johannsson, G. Articles by Albertsson-Wikland, K.

Discontinuation of Growth Hormone (GH) Treatment: Metabolic Effects in GH-Deficient and GH-Sufficient Adolescent Patients Compared with Control Subjects¹

Research Center for Endocrinology and Metabolism (G.J., B.-Å.) and Pediatric Growth Research Center (K.A.-W.), Sahlgrenska University Hospital, SE-413–45 Goteborg, Sweden

Address all correspondence and requests for reprints to: Gudmundur Johannsson, M.D., Ph.D., Research Center for Endocrinology and Metabolism, Sahlgrenska University Hospital, SE-413 45 Goteborg, Sweden. E-mail: gudmundur.johannsson{at}medic.gu.se

The need for continuing GH replacement in patients with childhood-onset GH deficiency continuing into adulthood has been recognized. The metabolic consequences of discontinuing GH in adolescent patients with childhood-onset GH deficiency and short stature were examined over a period of 2 yr. Forty adolescents (aged 16–21 yr) receiving GH treatment for more than 3 yr and 16 closely matched healthy controls were studied. After a baseline visit, GH treatment was discontinued. The patients were then examined with the same protocol once a year for 2 yr. Twenty-one patients had severe GH deficiency (GHD) into adulthood, whereas 19 patients were regarded as having sufficient endogenous GH secretion (GHS). After 2 yr without GH treatment, the serum insulin-like growth factor I level was lower in GHD than in both GHS and control subjects. Both before and 2 yr after GH treatment was discontinued, serum concentrations of total cholesterol (C), low density lipoprotein C, and apolipoprotein B were higher in the GHD than in both GHS and control subjects. Serum concentrations of high density lipoprotein C decreased in the GHD group and increased in the other 2 study groups. The amount of total body and abdominal fat mass throughout the study and the increment in these masses were more marked in the GHD than in the GHS and control subjects when GH treatment was discontinued.

The discontinuation of GH therapy in adolescents with severe GHD continuing into adulthood results over a period of 2 yr in the accumulation of important cardiovascular risk factors that are associated with GHD in adults.

This article has been cited by other articles:

				G S Conway, M Szarras-Czapnik, K Racz, A Keller, P Chanson, M Tauber, M Zacharin, and on behalf of the 1369 GHD to GHDA Transition Study Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency Eur. J. Endocrinol., June 1, 2009; 160(6): 899 - 907. [Abstract] [Full Text] [PDF]

				N. Moller and J. O. L. Jorgensen Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects Endocr. Rev., April 1, 2009; 30(2): 152 - 177. [Abstract] [Full Text] [PDF]

				C. Hoybye, P. Jonsson, J. P Monson, M. Koltowska-Haggstrom, V. Hana, M. Geffner, and R. Abs Impact of the primary aetiology upon the clinical outcome of adults with childhood-onset GH deficiency Eur. J. Endocrinol., November 1, 2007; 157(5): 589 - 596. [Abstract] [Full Text] [PDF]

				H. Urushihara, S. Fukuhara, S. Tai, S. Morita, and K. Chihara Heterogeneity in responsiveness of perceived quality of life to body composition changes between adult- and childhood-onset Japanese hypopituitary adults with GH deficiency during GH replacement Eur. J. Endocrinol., June 1, 2007; 156(6): 637 - 645. [Abstract] [Full Text] [PDF]

				S. Radovick and S. DiVall Approach to the Growth Hormone-Deficient Child during Transition to Adulthood J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1195 - 1200. [Abstract] [Full Text] [PDF]

				J. Svensson, G. Johannsson, A. Iranmanesh, K. Albertsson-Wikland, J. D Veldhuis, and B.-A. Bengtsson GH secretory pattern in young adults who discontinued GH treatment for GH deficiency and decreased longitudinal growth in childhood. Eur. J. Endocrinol., July 1, 2006; 155(1): 91 - 99. [Abstract] [Full Text] [PDF]

				M. Salerno, V. Esposito, V. Farina, G. Radetti, A. Umbaldo, D. Capalbo, L. Spinelli, S. Muzzica, G. Lombardi, and A. Colao Improvement of Cardiac Performance and Cardiovascular Risk Factors in Children with GH Deficiency after Two Years of GH Replacement Therapy: An Observational, Open, Prospective, Case-Control Study J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1288 - 1295. [Abstract] [Full Text] [PDF]

				R. Lanes, A. Soros, K. Flores, P. Gunczler, E. Carrillo, and J. Bandel Endothelial Function, Carotid Artery Intima-Media Thickness, Epicardial Adipose Tissue, and Left Ventricular Mass and Function in Growth Hormone-Deficient Adolescents: Apparent Effects of Growth Hormone Treatment on These Parameters J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3978 - 3982. [Abstract] [Full Text] [PDF]

				N. Mauras, O. H. Pescovitz, V. Allada, M. Messig, M. P. Wajnrajch, B. Lippe, and on behalf of the Transition Study Group Limited Efficacy of Growth Hormone (GH) during Transition of GH-Deficient Patients from Adolescence to Adulthood: A Phase III Multicenter, Double-Blind, Randomized Two-Year Trial J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3946 - 3955. [Abstract] [Full Text] [PDF]

				A. Colao, C. Di Somma, F. Rota, S. Di Maio, M. Salerno, A. Klain, S. Spiezia, and G. Lombardi Common Carotid Intima-Media Thickness in Growth Hormone (GH)-Deficient Adolescents: A Prospective Study after GH Withdrawal and Restarting GH Replacement J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2659 - 2665. [Abstract] [Full Text] [PDF]

				C. Franco, J. Brandberg, L. Lonn, B. Andersson, B.-A. Bengtsson, and G. Johannsson Growth Hormone Treatment Reduces Abdominal Visceral Fat in Postmenopausal Women with Abdominal Obesity: A 12-Month Placebo-Controlled Trial J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1466 - 1474. [Abstract] [Full Text] [PDF]

				A. Mukherjee, S. Tolhurst-Cleaver, W. D. J. Ryder, L. Smethurst, and S. M. Shalet The Characteristics of Quality of Life Impairment in Adult Growth Hormone (GH)-Deficient Survivors of Cancer and Their Response to GH Replacement Therapy J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1542 - 1549. [Abstract] [Full Text] [PDF]

				P E Clayton, R C Cuneo, A Juul, J P Monson, S M Shalet, and M Tauber Consensus statement on the management of the GH-treated adolescent in the transition to adult care Eur. J. Endocrinol., February 1, 2005; 152(2): 165 - 170. [Abstract] [Full Text] [PDF]

				M. Bohlooly-Y, B. Olsson, C. E.G. Bruder, D. Linden, K. Sjogren, M. Bjursell, E. Egecioglu, L. Svensson, P. Brodin, J. C. Waterton, et al. Growth Hormone Overexpression in the Central Nervous System Results in Hyperphagia-Induced Obesity Associated With Insulin Resistance and Dyslipidemia Diabetes, January 1, 2005; 54(1): 51 - 62. [Abstract] [Full Text] [PDF]

				A. F. Attanasio, E. Shavrikova, W. F. Blum, M. Cromer, C. J. Child, M. Paskova, J. Lebl, J. J. Chipman, the Hypopituitary Developmental Outcome Study Grou, and S. M. Shalet Continued Growth Hormone (GH) Treatment after Final Height Is Necessary to Complete Somatic Development in Childhood-Onset GH-Deficient Patients J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4857 - 4862. [Abstract] [Full Text] [PDF]

				P. V. Carroll, W. M. Drake, K. T. Maher, K. Metcalfe, N. J. Shaw, D. B. Dunger, T. D. Cheetham, C. Camacho-Hubner, M. O. Savage, and J. P. Monson Comparison of Continuation or Cessation of Growth Hormone (GH) Therapy on Body Composition and Metabolic Status in Adolescents with Severe GH Deficiency at Completion of Linear Growth J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3890 - 3895. [Abstract] [Full Text] [PDF]

				J. A.M. de Boer, C. B. Lambalk, H. H. Hendriks, C. van Aken, E. A. van der Veen, and J. Schoemaker Growth hormone secretion is impaired but not related to insulin sensitivity in non-obese patients with polycystic ovary syndrome Hum. Reprod., March 1, 2004; 19(3): 504 - 509. [Abstract] [Full Text] [PDF]

				S. G. Albert and A. D. Mooradian Low-Dose Recombinant Human Growth Hormone as Adjuvant Therapy to Lifestyle Modifications in the Management of Obesity J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 695 - 701. [Abstract] [Full Text] [PDF]

				M. Tauber, B. Jouret, A. Cartault, N. Lounis, M. Gayrard, C. Marcouyeux, C. Pienkowski, I. Oliver, P. Moulin, P. Otal, et al. Adolescents with Partial Growth Hormone (GH) Deficiency Develop Alterations of Body Composition after GH Discontinuation and Require Follow-Up J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5101 - 5106. [Abstract] [Full Text] [PDF]

				S. M. Shalet, E. Shavrikova, M. Cromer, C. J. Child, E. Keller, J. Zapletalova, T. Moshang, W. F. Blum, J. J. Chipman, C. A. Quigley, et al. Effect of Growth Hormone (GH) Treatment on Bone in Postpubertal GH-Deficient Patients: A 2-Year Randomized, Controlled, Dose-Ranging Study J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4124 - 4129. [Abstract] [Full Text] [PDF]

				Y. van Pareren, P. Mulder, M. Houdijk, M. Jansen, M. Reeser, and A. Hokken-Koelega Effect of Discontinuation of Growth Hormone Treatment on Risk Factors for Cardiovascular Disease in Adolescents Born Small for Gestational Age J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 347 - 353. [Abstract] [Full Text] [PDF]

				Y. K. van Pareren, S. M. P. F. de Muinck Keizer-Schrama, T. Stijnen, T. C. J. Sas, and S. L. S. Drop Effect of Discontinuation of Long-Term Growth Hormone Treatment on Carbohydrate Metabolism and Risk Factors for Cardiovascular Disease in Girls with Turner Syndrome J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5442 - 5448. [Abstract] [Full Text] [PDF]

				D. M. Cook Shouldn't Adults with Growth Hormone Deficiency Be Offered Growth Hormone Replacement Therapy? Ann Intern Med, August 6, 2002; 137(3): 197 - 201. [Abstract] [Full Text] [PDF]

				A. Colao, C. Di Somma, M. Salerno, L. Spinelli, F. Orio, and G. Lombardi The Cardiovascular Risk of GH-Deficient Adolescents J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3650 - 3655. [Abstract] [Full Text] [PDF]

				A. F. Attanasio, S. Howell, P. C. Bates, P. Frewer, J. Chipman, W. F. Blum, and S. M. Shalet Body Composition, IGF-I and IGFBP-3 Concentrations as Outcome Measures in Severely GH-Deficient (GHD) Patients after Childhood GH Treatment: A Comparison with Adult Onset GHD Patients J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3368 - 3372. [Abstract] [Full Text] [PDF]

				L. Hulthen, B.-A. Bengtsson, K. S. Sunnerhagen, L. Hallberg, G. Grimby, and G. Johannsson GH Is Needed for the Maturation of Muscle Mass and Strength in Adolescents J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4765 - 4770. [Abstract] [Full Text] [PDF]

				W. M. Drake, S. J. Howell, J. P. Monson, and S. M. Shalet Optimizing GH Therapy in Adults and Children Endocr. Rev., August 1, 2001; 22(4): 425 - 450. [Abstract] [Full Text] [PDF]

				L. Wiren, G. Johannsson, and B.-A. Bengtsson A Prospective Investigation of Quality of Life and Psychological Well-Being after the Discontinuation of GH Treatment in Adolescent Patients Who Had GH Deficiency during Childhood J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3494 - 3498. [Abstract] [Full Text] [PDF]

				A. M. Ahmad, R. Guzder, A. M. Wallace, J. Thomas, W. D. Fraser, and J. P. Vora Circadian and Ultradian Rhythm and Leptin Pulsatility in Adult GH Deficiency: Effects of GH Replacement J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3499 - 3506. [Abstract] [Full Text] [PDF]

				R. Lanes, P. Gunczler, E. Lopez, S. Esaa, O. Villaroel, and R. Revel-Chion Cardiac Mass and Function, Carotid Artery Intima-Media Thickness, and Lipoprotein Levels in Growth Hormone-Deficient Adolescents J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1061 - 1065. [Abstract] [Full Text]